DEST Destiny Pharma Plc

TIDMDEST

RNS Number : 4596D

Destiny Pharma PLC

29 June 2021

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Destiny Pharma to present at the Shares and AJ Bell Investor Webinar on 06 July 2021

Brighton, United Kingdom - 29 June 2021 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that its Chief Executive Officer, Neil Clark, will provide a live presentation on the Company at the Shares and AJ Bell Investor Evening Webinar on Tuesday, 06 July at 6:00 pm BST.

The Shares and AJ Bell Investor Evening Webinar is an opportunity for existing and potential investors to receive a business update from senior executives of listed PLCs.

Attendees will have the opportunity to ask questions to the presenters via an online chat window during the webinar.

Shareholders and potential investors can register to join the webinar for free at:

https://www.sharesmagazine.co.uk/events/event/shares-investor-evening--webinar-060721

-ENDS-

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0) 1273 704 440

pressoffice@destinypharma.com

Optimum Strategic Communications

Mary Clark/ Hollie Vile/ Manel Mateus

+44 (0) 203 174 1789

destinypharma@optimumcomms.com

About Destiny Pharma plc

Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US, and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects.

   For further information on the company, please visit   https://www.destinypharma.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCPPUPPQUPGUMB

(END) Dow Jones Newswires

June 29, 2021 03:24 ET (07:24 GMT)

Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De May 2023 a May 2024